Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03467022|
Recruitment Status : Completed
First Posted : March 15, 2018
Last Update Posted : March 26, 2018
Scurvy, or latent scurvy, may be underestimated in developed countries, but continue to be described, often as case report. Little is known about the prevalence of vitamin C deficiency in a specific population as withdrawal alcoholics and about his possible consequences, latent scurvy.
In an observational study, the investigators will evaluate prospectively the prevalence of vitamin C deficiency in alcoholic withdrawal patients, its correlation with latent scurvy, mainly tiredness and weakness, and the evolution of the latter at three months after oral vitamin C supplementation.
|Condition or disease||Intervention/treatment|
|Alcoholics||Drug: Vitamin C|
This study aims to examine:
- the level of plasma vitamin C for patients that volunteered for alcohol withdrawal. Measurement of vitamin C plasma level will be performed as soon as possible after the agreement as the discussion with the physician could lead to a change in dietary habits. It will be performed by high-pressure liquid chromatography (Cerba Laboratory, F-Cergy Pontoise) according to Lee et al.
- the correlation between plasma vitamin C level and clinical signs of scurvy, especially signs of latent scurvy like tiredness, leg pain, gums involvement, previously loss of healthy teeth. These signs will be recorded in a structured questionnaire during the first consultation, before knowing the laboratory result patient. All patients who are smoking will perform systematic otorhinolaryngology examination in search of cancer. Other reasons for weakness will be searched by clinical anamneses, body examination, blood probe and abdominal ultrasound examination.
- the decrease or disappearance of tiredness and/or purpura and/or gums involvement will be studied after vitamin C supplementation in patients whose vitamin C plasma determination is under normal levels and that don't have another explanation for their tiredness. Patients will be evaluated after receiving 1 g oral vitamin C for at least three months.
Ethical considerations The study was approved by the institutional ethics committee of the clinic and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained before entry study and each participant agreed to pay for the plasma vitamin C determination.
Dissemination findings Findings for the present study will be reported in manuscripts that will be submitted for publication to a leading medical or nutrition journal in a appropriate field (i.e.alcoholism, nutrition). In addition, findings will be presented as abstracts, posters and presentations at conferences.
|Study Type :||Observational|
|Actual Enrollment :||47 participants|
|Official Title:||Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy: A STROBE Compliant Study|
|Actual Study Start Date :||January 2, 2014|
|Actual Primary Completion Date :||November 30, 2016|
|Actual Study Completion Date :||March 30, 2017|
- Drug: Vitamin C
Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three monthsOther Name: Ascorbic acid
- Plasma vitamin C concentration in alcoholic withdrawal patients [ Time Frame: 23 months (beginning till end of the recruitment) ]
Plasma vitamin C determination will be performed as soon as possible after the consent of the patient.
Measurement of vitamin C will be performed by high-pressure liquid chromatography (Cerba Laboratory, F-Cergy Pontoise) with a Roche Fara centrifugal analyzer
- Correlation between plasma vitamin C and latent scurvy symptoms [ Time Frame: 23 months (beginning till end of the recruitment) ]Using Excel, we will apply a transformation to convert status of tiredness, skin symptoms and gum involvement/ loss of healthy teeth into binary variables.This is in order to provide a better graphical representation. One graph will be displayed per symptom. When it comes to the binary variables, 0 corresponds to " absence of tiredness" whereas 1 corresponds to "presence of tiredness" for the first graph; 0 corresponds to "absence of purpura" whereas 1 means "presence of purpura " for the second graph; 0 corresponds to "absence of gums involvement or absence of loss of healthy teeth "whereas 1 means "presence of gums involvement or loss of healthy teeth".
- Questionnaire detailing the evolution of tiredness/purpura/gums involvement after supplementation with 1g/day of oral vitamin C for three months [ Time Frame: 3 to 4 months for each patient ]Deficient or depleted patients will be supplemented with 1g/day of oral vitamin C for three months. When being examined after three months, the patients will be asked about the feeling of tiredness and the evolution of purpura and gums involvement will be investigated. Results will be expressed with binary variables (0 corresponds to a non-improvement state whereas 1 corresponds to an improvement state).
Biospecimen Retention: Samples Without DNA
Measurement of vitamin C ail be performed by high-pressure liquid chromatography (Cerba Laboratory, F-Cergy Pontoise).
Results are expressed in micromol per liter (µmol/L) with a normal range from 26,4 to 84,0µmol/L. These measures are in correlation with those quoted by O.Frain et al concerning healthy French men and women (5 to 15 mg/L equal to 28,4 -85,5µmol/L). According to Johnston's criteria, plasma vitamin C level lower than 11,4µmol/L (2mg/L) will be considered as vitamin C deficiency, lower than 28,4µmol/L (5 mg/L) as vitamin C depletion. The lower limit of quantification is 3µmol/L (< 0,5 mg /L); the patient is considered biologically as having scurvy or at high risk for development of scurvy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03467022
|Principal Investigator:||Daniel Battistelli, MD||Nouvelle Clinique des Trois Frontieres Saint-Louis|